Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)

Phase Distribution

Ph phase_2
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

terminated150%
active_not_recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
active_not_recruitingphase_2

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

NCT03040973
terminatedphase_1

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

NCT02335944

Clinical Trials (2)

Showing 2 of 2 trials
NCT03040973Phase 2

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Active Not Recruiting
NCT02335944Phase 1

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2